Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Pressemeddelelse

Annexin Pharmaceuticals AB: BioStock: Annexin confirms promising results and strengthens financial position

Annexin Pharmaceuticals

Annexin Pharmaceuticals announces that the phase IIa study with its drug candidate ANXV for the eye disease retinal vein occlusion (RVO) has achieved all primary objectives. The results confirm previously reported topline data, demonstrating strong signals of effect and a favourable safety profile. The company has also announced a capital raise of approximately SEK 50 million, primarily for continued investments in the RVO program, a focused clinical study on diabetic retinopathy, but also for studies exploring the potential of ANXV treatment in cancer and sickle cell anemia.

Read the article at biostock.se:

https://www.biostock.se/en/2025/02/annexin-confirms-promising-results-and-strengthens-financial-position/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.